Studies have shown that the antitumor function of NK cells from peripheral blood of patients with ovarian cancer can be significantly augmented by in vitro stimulation with recombinant IL-2 [31,32], and that primary malignant ovarian cells are susceptible to killing by allogeneic NK lymphocytes. This evidence concerns the gene IL2 and ovarian carcinoma.